155 related articles for article (PubMed ID: 38050555)
21. Current Status of Adverse Event Profile of Cyclosporine in Kidney, Stem Cell, and Heart Transplantations Using the Japanese Pharmacovigilance Database.
Niinomi I; Oyama S; Inada A; Wakabayashi T; Iida T; Kambara H; Uchida M; Sano Y; Hosohata K
Cureus; 2022 Sep; 14(9):e29383. PubMed ID: 36159360
[TBL] [Abstract][Full Text] [Related]
22. Post-marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Zhuang W; Xu J; Wu Y; Yang J; Lin X; Liao Y; Wan J; Weng L; Lin W
Br J Clin Pharmacol; 2023 Sep; 89(9):2830-2842. PubMed ID: 37170890
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database.
Inada A; Hosohata K; Oyama S; Niinomi I; Mori Y; Yamaguchi Y; Uchida M; Iwanaga K
Ther Clin Risk Manag; 2019; 15():59-64. PubMed ID: 30636879
[TBL] [Abstract][Full Text] [Related]
24. Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance.
Wakabayashi T; Nakatsuji T; Kambara H; Niinomi I; Oyama S; Inada A; Ueno S; Uchida M; Iwanaga K; Iida T; Hosohata K
Curr Rev Clin Exp Pharmacol; 2022; 17(2):144-148. PubMed ID: 33588740
[TBL] [Abstract][Full Text] [Related]
25. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
26. Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database.
Pugi A; Bonaiuti R; Maggini V; Moschini M; Tuccori M; Leone R; Rossi M; Motola D; Piccinni C; Ferrazin F; Sottosanti L; Mugelli A; Vannacci A; Lapi F
Am J Health Syst Pharm; 2013 Jun; 70(12):1039-46. PubMed ID: 23719881
[TBL] [Abstract][Full Text] [Related]
27. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
28. An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on Masking Signal Detection in EudraVigilance.
Micallef B; Dogné JM; Sultana J; Straus SMJM; Nisticò R; Serracino-Inglott A; Borg JJ
Drug Saf; 2023 Nov; 46(11):1089-1103. PubMed ID: 37707778
[TBL] [Abstract][Full Text] [Related]
29. [Association between Selective Beta-adrenergic Drugs and Blood Pressure Elevation: Data Mining of the Japanese Adverse Drug Event Report (JADER) Database].
Ohyama K; Inoue M
Yakugaku Zasshi; 2016; 136(7):1065-71. PubMed ID: 27374969
[TBL] [Abstract][Full Text] [Related]
30. Association of Aggression and Antiepileptic Drugs: Analysis Using the Japanese Adverse Drug Event Report (JADER) Database.
Kawada K; Ishida T; Jobu K; Ohta T; Fukuda H; Morisawa S; Kawazoe T; Tamura N; Miyamura M
Biol Pharm Bull; 2022; 45(6):720-723. PubMed ID: 35650100
[TBL] [Abstract][Full Text] [Related]
31. A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data.
Wei C; Liu Y; Jiang A; Wu B
Int J Clin Pharm; 2022 Jun; 44(3):709-716. PubMed ID: 35364753
[TBL] [Abstract][Full Text] [Related]
32. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
Nagai J; Ishikawa Y
PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
[TBL] [Abstract][Full Text] [Related]
33. Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS).
Ma P; Pan X; Liu R; Qu Y; Xie L; Xie J; Cao L; Chen Y
Front Pharmacol; 2022; 13():1017889. PubMed ID: 36467087
[No Abstract] [Full Text] [Related]
34. Disproportionality Analysis of Safety Signals for a Wide Variety of Opioid-Related Adverse Events in Elderly Patients Using the Japanese Adverse Drug Event Report (JADER) Database.
Omoto T; Asaka J; Sakai T; Sato F; Goto N; Kudo K
Biol Pharm Bull; 2021; 44(5):627-634. PubMed ID: 33952819
[TBL] [Abstract][Full Text] [Related]
35. Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
Gastaldon C; Raschi E; Kane JM; Barbui C; Schoretsanitis G
Psychother Psychosom; 2021; 90(1):41-48. PubMed ID: 32854103
[TBL] [Abstract][Full Text] [Related]
36. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Safety Profiles of New Oral Anticoagulants with Warfarin Using the Japanese Spontaneous Reporting Database.
Hosohata K; Oyama S; Niinomi I; Wakabayashi T; Inada A; Iwanaga K
Clin Drug Investig; 2019 Jul; 39(7):665-670. PubMed ID: 31054085
[TBL] [Abstract][Full Text] [Related]
38. Identifying Crude Drugs in Kampo Medicines Associated with Drug-Induced Liver Injury Using the Japanese Adverse Drug Event Report Database: A Comprehensive Survey.
Kimura K; Kikegawa M; Kan Y; Uesawa Y
Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242461
[TBL] [Abstract][Full Text] [Related]
39. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
[TBL] [Abstract][Full Text] [Related]
40. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting.
Tuccori M; Lapi F; Testi A; Coli D; Moretti U; Vannacci A; Motola D; Salvo F; Rivolta AL; Blandizzi C; Mugelli A; Del Tacca M
Drug Saf; 2008; 31(12):1115-23. PubMed ID: 19026028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
